Aromasin
information and resources from the National Cancer Institute
Aromasin
(Other name for: exemestane)
exemestane
Treatment of advance breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
Pharmacia & Upjohn Company Oct 21 1999
|
|
|
|
news articles
Aromasin® Improves Breast Cancer Outcomes Without Compromising ... Feb 28, 2006
Cancer Consultants (press release), Breast cancer patients who switched to Aromasin® (exemestane) after 2-3 years of Nolvadex® (tamoxifen) reported a similar quality of life to patients who ...
Neoadjuvant Aromatase Inhibitors May Be as Effective as ... Mar 27, 2006
DG News ...to pre-operative treatment with either an aromatase inhibitor -- consisting of either anastrazole (Arimidex) or exemestane (Aromasin) -- or chemotherapy. ...
Exemestane May Help Downgrade Tumours Scheduled for Mastectomy to ... Mar 27, 2006
DG News NICE, FRANCE -- March 27, 2006 -- The aromatase inhibitor exemestane (Aromasin) could make breast-conserving surgery possible in breast cancer patients with ...
Thwarting further breast cancer Mar 15, 2006
Sarasota Herald-Tribune, ...protein. Three new drugs -- Femara, Arimidex and Aromasin -- block the conversion of androgens (male hormones) into estrogen. The ...
New cancer drugs reduce recurrence Mar 6, 2006
Contra Costa Times, Three new drugs -- Femara, Arimidex and Aromasin -- block the conversion of androgens (male hormones) to estrogen. Women do make male hormones. ...
ExCel Breast Cancer Prevention Study Back On Track Mar 4, 2006
Medical News Today (press release), ExCel is back on track with a redesigned protocol that will look at the effectiveness of one of the aromatase inhibitors, exemestane (AROMASIN®), as a ...
Novartis to compare cancer drug Femara with AstraZeneca drug Mar 20, 2006
MarketWatch Another drug in this class is Pfizer Inc.'s (PFE) Aromasin. Novartis, based in Basel, Switzerland, said the study will look at 4,000 patients around the world. ...
(PZ) VioQuest Pharmaceuticals Appoints an Industry Veteran as ... Mar 15, 2006
Houston Chronicle, She was previously senior medical director for Pfizer, where she was responsible for US development of Aromasin, an aromatase inhibitor for breast cancer, and ...
New Drugs For Breast Cancer 21 Dec 2005
WFtv.com, ...estrogen. There are three AIs approved by the FDA including anastrozole (Arimidex), exemestane (Aromasin) and letrozole (Femara). ...
Hope lives for cancer patients Dec 18, 2005
Birmingham News, ...cancer lesions. I've taken Tamoxifen, Femara and Aromasin. When one drug quits working, Dr. Falkson switches me to another. On Friday ...
Stopping Tamoxifen May Help Breast Cancer Dec 9, 2005
Herald News Daily, ...does. Three brands are available: AstraZeneca PLC‘s Arimidex, Pfizer Inc.‘s Aromasin and Novartis Pharmaceuticals‘ Femara. ...
Femara gets approval for early adjuvant use in UK Dec 8, 2005
Pharma Times (subscription), ...profile should aid Femara as it competes with the other main aromatase inhibitors, AstraZeneca's Arimidex (anastrozole) and Pfizer's Aromasin (exemestane, and ...
Researchers seek volunteers for breast cancer study Dec 14, 2005
Newark Star Ledger, ...responding to tamoxifen therapy, Lasser said. Exemestane is a hormonal drug sold under the brand Aromasin. It belongs to a newer ...
New strategy for boosting breast cancer survival Dec 9, 2005
MSNBC ...does. Three brands are available: AstraZeneca PLC’s Arimidex, Pfizer Inc.’s Aromasin and Novartis Pharmaceuticals’ Femara. ...
A switch in cancer drugs could extend women's lives Dec 9, 2005
Houston Chronicle, ...tamoxifen does. Three brands are available: AstraZeneca's Arimidex, Pfizer's Aromasin and Novartis Pharmaceuticals' Femara. Doctors ...
Health campaigns face axe in cash crisis Dec 10, 2005
The Sunday Times, ...because the DoH has insisted it should carry out a large, simultaneous study into Arimidex and two similar hormone-based anti-cancer drugs, Femara and Aromasin ...
New breast cancer drug trial seeks volunteers Dec 5, 2005
Salem News, A new international trial is underway to find out if one particular aromatase inhibitor, called exemestane (marketed as Aromasin by Pfizer), would do just that ...
|
|
